Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study.

Autores de IIS La Fe

• Mª Isabel Izquierdo Macián

  Autor

• Antonio Nieto García

  Autor

Participantes ajenos a IIS La Fe

• Potter P
• Maspero JF
• Vermeulen J
• Barkai L
• Németh I
• Baillieau RA
• Garde JM
• Giralt J
• Doménech A

Grupos

• Alergia y enfermedades respiratorias de la Infancia

• Perinatología

Abstract

Allergic rhinitis (AR) is one of the most common chronic diseases in childhood. No large, multicentre clinical trials in children with persistent allergic rhinitis (PER) have previously been performed. Rupatadine, a newer second-generation antihistamine, effective and safe in adults, is a promising treatment for children with AR. The aim of the present study was to evaluate the efficacy and safety of a new rupatadine oral solution in children aged 6-11 yr with PER.